{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:02:41Z","timestamp":1765976561876,"version":"3.48.0"},"reference-count":39,"publisher":"Walter de Gruyter GmbH","issue":"3","funder":[{"DOI":"10.13039\/501100005712","name":"University of Jordan","doi-asserted-by":"crossref","award":["Unassigned"],"award-info":[{"award-number":["Unassigned"]}],"id":[{"id":"10.13039\/501100005712","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_hmbci-2021-0090_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aimed to evaluate the levels of serum lipoprotein a, LP (a), in Jordanian patients with type 2 diabetes mellitus (DM); and to examine its relation to glycemic control, metabolic syndrome (MS) and duration of DM. The LP (a)\u00a0is considered one of the independent risk factors for coronary artery disease (CAD) in the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2021-0090_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Fasting blood samples were drawn from 51 diabetic patients with type 2 DM and 31 non-diabetic age and sex control subjects. Serum LP (a)\u00a0was measured along\u00a0with other parameters, including triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c) and glycosylated haemoglobin (HbA\n                      <jats:sub>1c<\/jats:sub>\n                      ). Correlation analyses were performed between LP (a)\u00a0and the various variables measured.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2021-0090_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      LP (a)\u00a0measurement showed a skewed distribution towards the lower levels in both groups. Mean LP (a)\u00a0levels showed a statistically insignificant difference between the two groups. No correlations of LP (a)\u00a0were observed with age, sex or body mass index (BMI). No correlations of LP (a)\u00a0with LDL-c, HDL-c, TG, TC, MS, DM duration or HbA\n                      <jats:sub>1c<\/jats:sub>\n                      were observed. The LP (a)\u00a0serum levels were significantly higher in type 2 diabetic patients with retinopathy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2021-0090_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LP (a)\u00a0serum levels are not increased in type 2 diabetic patients; so, LP (a)\u00a0may not be a reliable marker for early therapeutic interventions in DM patients, even in high-risk for thrombosis groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/hmbci-2021-0090","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T16:24:10Z","timestamp":1650039850000},"page":"263-271","source":"Crossref","is-referenced-by-count":3,"title":["Clinical investigation of lipoprotein (a)\u00a0levels in type 2 diabetics for cardiovascular diseases prediction and prognosis"],"prefix":"10.1515","volume":"43","author":[{"given":"Yasser","family":"Bustanji","sequence":"first","affiliation":[{"name":"Department of Basic Medical Sciences , College of Medicine, University of Sharjah , Sharjah , UAE"},{"name":"School of Pharmacy , The University of Jordan , Amman , Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor","family":"Barham","sequence":"additional","affiliation":[{"name":"School of Pharmacy , The University of Jordan , Amman , Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman Y.","family":"Abu-rish","sequence":"additional","affiliation":[{"name":"School of Pharmacy , The University of Jordan , Amman , Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelkareem","family":"Alhyari","sequence":"additional","affiliation":[{"name":"College of Medicine , The University of Jordan , Amman , Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basil","family":"Albustanji","sequence":"additional","affiliation":[{"name":"Faculty of Medicine , Mutah University , Karak , Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majd","family":"Alnajjar","sequence":"additional","affiliation":[{"name":"Hamdi Mango Center for Scientific Research , The University of Jordan , Amman , Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bashaer","family":"Abu-irmaileh","sequence":"additional","affiliation":[{"name":"Hamdi Mango Center for Scientific Research , The University of Jordan , Amman , Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waseem","family":"El-Huneidi","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences , College of Medicine, University of Sharjah , Sharjah , UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Abu-Gharbieh","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences , College of Medicine, University of Sharjah , Sharjah , UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Mohammad","sequence":"additional","affiliation":[{"name":"School of Pharmacy , The University of Jordan , Amman , Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Fararjeh","sequence":"additional","affiliation":[{"name":"Al-Quds Medical Labs , AL-Zarqa , Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ala","family":"Issa","sequence":"additional","affiliation":[{"name":"School of Pharmacy , The University of Jordan , Amman , Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Semreen","sequence":"additional","affiliation":[{"name":"College of Pharmacy , University of Sharjah , Sharjah , UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4691-5030","authenticated-orcid":false,"given":"Hana","family":"Bajes","sequence":"additional","affiliation":[{"name":"School of Pharmacy , The University of Jordan , Amman , Jordan"},{"name":"Science Department , Atlantic Cape Community College , Mays Landing , NJ 08330 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"2025121207225430525_j_hmbci-2021-0090_ref_001","doi-asserted-by":"crossref","unstructured":"Mohamed, J, Nazratun Nafizah, AH, Zariyantey, AH, Budin, SB. Mechanisms of diabetes-induced liver damage: the role of oxidative stress and inflammation. Sultan Qaboos Univ Med J 2016;16:e132\u201341. https:\/\/doi.org\/10.18295\/squmj.2016.16.02.002.","DOI":"10.18295\/squmj.2016.16.02.002"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_002","doi-asserted-by":"crossref","unstructured":"Berg, K. A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand 2009;59:369\u201382. https:\/\/doi.org\/10.1111\/j.1699-0463.1963.tb01808.x.","DOI":"10.1111\/j.1699-0463.1963.tb01808.x"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_003","unstructured":"McCormick, SP. Lipoprotein(a): biology and clinical importance. Clin Biochem Rev 2004;25:69\u201380."},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_004","doi-asserted-by":"crossref","unstructured":"Dugani, SB, Akinkuolie, AO, Paynter, N, Glynn, RJ, Ridker, PM, Mora, S. Association of lipoproteins, insulin resistance, and rosuvastatin with incident type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol 2016;1:136\u201345. https:\/\/doi.org\/10.1001\/jamacardio.2016.0096.","DOI":"10.1001\/jamacardio.2016.0096"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_005","doi-asserted-by":"crossref","unstructured":"Kronenberg, F. Human genetics and the causal role of lipoprotein(a) for various diseases. Cardiovasc Drugs Ther 2016;30:87\u2013100. https:\/\/doi.org\/10.1007\/s10557-016-6648-3.","DOI":"10.1007\/s10557-016-6648-3"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_006","doi-asserted-by":"crossref","unstructured":"Vaverkov\u00e1, H, Kar\u00e1sek, D, Halenka, M, Cib\u00ed\u010dkov\u00e1, L, Kub\u00ed\u010dkov\u00e1, V. Inverse association of lipoprotein (a)\u00a0with markers of insulin resistance in dyslipidemic subjects. Physiol Res 2017:S113\u201320.","DOI":"10.33549\/physiolres.933583"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_007","doi-asserted-by":"crossref","unstructured":"Aleidi, SM, Shayeb, E, Bzour, J, Abu-Rish, EY, Hudaib, M, Al Alawi, S, et al.. Serum level of insulin-like growth factor-I in type 2 diabetic patients: impact of obesity. Horm Mol Biol Clin Invest 2019;39:1\u20138. https:\/\/doi.org\/10.1515\/hmbci-2019-0015.","DOI":"10.1515\/hmbci-2019-0015"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_008","doi-asserted-by":"crossref","unstructured":"Muhanhali, D, Zhai, T, Cai, Z, Ling, Y. Lipoprotein(a) concentration is associated with risk of type 2 diabetes and cardiovascular events in a Chinese population with very high cardiovascular risk. Endocrine 2020;69:63\u201372. https:\/\/doi.org\/10.1007\/s12020-020-02286-5.","DOI":"10.1007\/s12020-020-02286-5"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_009","doi-asserted-by":"crossref","unstructured":"Kaya, A, Onat, A, Y\u00fcksel, H, Can, G, Y\u00fcksel, M, Ademo\u011flu, E. Lipoprotein(a)-activated immunity, insulin resistance and new-onset diabetes. PGM (Postgrad Med) 2017;129:611\u20138. https:\/\/doi.org\/10.1080\/00325481.2017.1342508.","DOI":"10.1080\/00325481.2017.1342508"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_010","doi-asserted-by":"crossref","unstructured":"Saeed, A, Sun, W, Agarwala, A, Virani, SS, Nambi, V, Coresh, J, et al.. Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: the atherosclerosis risk in communities study. Atherosclerosis 2019;282:52\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.12.022.","DOI":"10.1016\/j.atherosclerosis.2018.12.022"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_011","doi-asserted-by":"crossref","unstructured":"Roy, V, Biswas, J, Saraf, A. Comparative evaluation on lipid profile between diabetic and nondiabetic patients, signalizing some common physiological complications intended towards diabetes: a case study from Raipur, C.G., India. Ambient Sci 2019;06 & 06h.","DOI":"10.21276\/ambi.2018.05.sp1.ra03"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_012","doi-asserted-by":"crossref","unstructured":"Aleidi, SM, Shayeb, E, Bzour, J, Abu-Rish, EY, Hudaib, M, Al Alawi, S, et al.. Serum level of insulin-like growth factor-I in type 2 diabetic patients: impact of obesity. Horm Mol Biol Clin Invest 2019;39. article # 2019-0015.","DOI":"10.1515\/hmbci-2019-0015"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_013","doi-asserted-by":"crossref","unstructured":"Fonseca, L, Paredes, S, Vilaverde, J, Alves, M, Oliveira, JC, Palma, I. Type 2 diabetes and lipid profile: is low-density lipoprotein - cholesterol enough? Atherosclerosis 2018;275:e200.","DOI":"10.1016\/j.atherosclerosis.2018.06.620"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_014","doi-asserted-by":"crossref","unstructured":"Liu, C, Xu, M-X, He, Y-M, Zhao, X, Du, X-J, Yang, X-J. Lipoprotein (a)\u00a0is not significantly associated with type 2 diabetes mellitus: cross-sectional study of 1604 cases and 7983 controls. Acta Diabetol 2017;54:443\u201353.","DOI":"10.1007\/s00592-017-0965-2"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_015","doi-asserted-by":"crossref","unstructured":"Paige, E, Masconi, KL, Tsimikas, S, Kronenberg, F, Santer, P, Weger, S, et al.. Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol 2017;16:38.","DOI":"10.1186\/s12933-017-0520-z"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_016","doi-asserted-by":"crossref","unstructured":"Aleidi, S, Issa, A, Bustanji, H, Khalil, M, Bustanji, Y. Adiponectin serum levels correlate with insulin resistance in type 2 diabetic patients. Saudi Pharmaceut J 2015;23:250\u20136.","DOI":"10.1016\/j.jsps.2014.11.011"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_017","doi-asserted-by":"crossref","unstructured":"Rajappa, M, Sridhar, MG, Balachander, J, Sethuraman, KR. Lipoprotein (a)\u00a0and comprehensive lipid tetrad index as a marker for coronary artery disease in NIDDM patients in South India. Clin Chim Acta 2006;372:70\u20135.","DOI":"10.1016\/j.cca.2006.03.019"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_018","doi-asserted-by":"crossref","unstructured":"Levitsky, LL, Scanu, AM, Gould, SH. Lipoprotein(a) levels in black and white children and adolescents with IDDM. Diabetes Care 1991;14:283\u20137.","DOI":"10.2337\/diacare.14.4.283"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_019","doi-asserted-by":"crossref","unstructured":"Haffner, SM, Tuttle, KR, Rainwater, DL. Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects. Diabetes Care 1991;14:302\u20137.","DOI":"10.2337\/diacare.14.4.302"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_020","doi-asserted-by":"crossref","unstructured":"Selvin, E, Coresh, J, Golden, SH, Boland, LL, Brancati, FL, Steffes, MW. Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the atherosclerosis risk in communities study. Diabetes Care 2005;28:1965\u201373.","DOI":"10.2337\/diacare.28.8.1965"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_021","doi-asserted-by":"crossref","unstructured":"Smaoui, M, Hammami, S, Chaaba, R, Attia, N, Hamda, KB, Masmoudi, AS, et al.. Lipids and lipoprotein(a) concentrations in Tunisian type 2 diabetic patients. J Diabetes Complicat 2004;18:258\u201363.","DOI":"10.1016\/S1056-8727(03)00075-8"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_022","doi-asserted-by":"crossref","unstructured":"Erem, C, Hac\u0131hasano\u011flu, A, \u00c7elik, \u015e, Oval\u0131, E, Ers\u00f6z, H\u00d6, Ukin\u00e7, K, et al.. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Med Princ Pract 2004;14:22\u201330.","DOI":"10.1159\/000081919"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_023","doi-asserted-by":"crossref","unstructured":"Ramirez, LC. Lipoprotein (a)\u00a0levels in diabetes mellitus: relationship to metabolic control. Ann Intern Med 1992;117:42.","DOI":"10.7326\/0003-4819-117-1-42"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_024","doi-asserted-by":"crossref","unstructured":"Chandni, R, Ramamoorthy, KP. Lipoprotein(a) in type 2 diabetic subjects and its relationship to diabetic microvascular complications. World J Diabetes 2012;3:105\u20139.","DOI":"10.4239\/wjd.v3.i5.105"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_025","doi-asserted-by":"crossref","unstructured":"Lim, T-S, Yun, J-S, Cha, S-A, Song, K-H, Yoo, K-D, Ahn, Y-B, et al.. Elevated lipoprotein(a) levels predict cardiovascular disease in type 2 diabetes mellitus: a 10-year prospective cohort study. Korean J Intern Med 2016;31:1110\u20139.","DOI":"10.3904\/kjim.2016.030"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_026","unstructured":"Nasri, H. Association of serum lipoprotein (a)\u00a0with hypertension in diabetic patients. Saudi J Kidney Dis Transpl 2008;19:420\u20137."},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_027","doi-asserted-by":"crossref","unstructured":"Habib, SS, Aslam, M. Lipids and lipoprotein(a) concentrations in Pakistani patients with type 2 diabetes mellitus. Diabetes Obes Metabol 2004;6:338\u201343.","DOI":"10.1111\/j.1462-8902.2004.00352.x"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_028","doi-asserted-by":"crossref","unstructured":"Albahrani, A, Alkindi, M, Marks, E, Alyahyaee, S, Shenkin, A. Lipoprotein(a): an independent risk factor for ischemic heart disease that is dependent on triglycerides in subjects with type 2 diabetes mellitus. Lipids Health Dis 2007;6:26.","DOI":"10.1186\/1476-511X-6-26"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_029","doi-asserted-by":"crossref","unstructured":"Abdella, NA, Mojiminiyi, OA, Akanji, AO, Al Mohammadi, H, Moussa, MAA. Serum lipoprotein(a) concentration as a cardiovascular risk factor in Kuwaiti Type 2 diabetic patients. J\u00a0Diabetes Complicat 2001;15:270\u20136.","DOI":"10.1016\/S1056-8727(01)00162-3"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_030","doi-asserted-by":"crossref","unstructured":"Sunayama, S, Daida, H, Mokuno, H, Miyano, H, Yokoi, H, Lee, YJ, et al.. Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women\u00a0\u226555 years of age. Circulation 1996;94:1263\u20138.","DOI":"10.1161\/01.CIR.94.6.1263"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_031","doi-asserted-by":"crossref","unstructured":"Bayrak, A, Aldemir, D, Bayrak, T, \u00c7orak\u00e7\u0131, A, Dursun, P. The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a)\u00a0in Turkish postmenopausal women. Arch Gynecol Obstet 2006;274:289\u201396.","DOI":"10.1007\/s00404-006-0187-2"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_032","doi-asserted-by":"crossref","unstructured":"Ushioda, M, Makita, K, Takamatsu, K, Horiguchi, F, Aoki, D. Serum lipoprotein(a) dynamics before\/after menopause and long-term effects of hormone replacement therapy on lipoprotein(a) levels in middle-aged and older Japanese women. Horm Metab Res 2006;38:581\u20136.","DOI":"10.1055\/s-2006-950504"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_033","doi-asserted-by":"crossref","unstructured":"Imperatore, G, Rivellese, A, Galasso, R, Celentano, E, Iovine, C, Ferrara, A, et al.. Lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus and borderline hyperglycemia: a population-based study. Metabolism 1995;44:1293\u20137.","DOI":"10.1016\/0026-0495(95)90032-2"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_034","doi-asserted-by":"crossref","unstructured":"Poznyak, A, Grechko, AV, Poggio, P, Myasoedova, VA, Alfieri, V, Orekhov, AN. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci 2020;21:1835.","DOI":"10.3390\/ijms21051835"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_035","unstructured":"Erg\u00fcn, UG, Ozt\u00fcz\u00fcn, S, Seydaoglu, G. Lipoprotein (A)\u00a0levels in type 2 diabetic patients with diabetic retinopathy. Med J Malaysia 2004;59:406\u201310."},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_036","doi-asserted-by":"crossref","unstructured":"Haffner, SM, Klein, BEK, Moss, SE, Klein, R. LP (a)\u00a0is not related to retinopathy in diabetic subjects. Eur J Ophthalmol 1995;5:119\u201323.","DOI":"10.1177\/112067219500500209"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_037","doi-asserted-by":"crossref","unstructured":"Kim, CH, Park, HJ, Park, JY, Hong, SK, Yoon, YH, Lee, KU. High serum lipoprotein(a) levels in Korean type 2 diabetic patients with proliferative diabetic retinopathy. Diabetes Care 1998;21:2149\u201351.","DOI":"10.2337\/diacare.21.12.2149"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_038","doi-asserted-by":"crossref","unstructured":"Moosaie, F, Davatgari, RM, Firouzabadi, FD, Esteghamati, S, Deravi, N, Meysamie, A, et al.. Lipoprotein(a) and apolipoproteins as predictors for diabetic retinopathy and its severity in adults with type 2 diabetes: a case-cohort study. Can J Diabetes 2020;44:414\u201321.","DOI":"10.1016\/j.jcjd.2020.01.007"},{"key":"2025121207225430525_j_hmbci-2021-0090_ref_039","unstructured":"Zarich, SW. Treating the diabetic patient: appropriate care for glycemic control and cardiovascular disease risk factors. Rev Cardiovasc Med 2003;4(6 Suppl):S19\u201328."}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2021-0090\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2021-0090\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:18:20Z","timestamp":1765527500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2021-0090\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,4,14]]},"published-print":{"date-parts":[[2022,9,28]]}},"alternative-id":["10.1515\/hmbci-2021-0090"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2021-0090","relation":{},"ISSN":["1868-1891"],"issn-type":[{"type":"electronic","value":"1868-1891"}],"subject":[],"published":{"date-parts":[[2022,4,15]]}}}